Trial Profile

A multicenter, observational, prospective, open-label study of Safinamide on non-motor symptoms in Parkinson's disease patients in Spian

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Safinamide (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms SAFINONMOTOR

Most Recent Events

01 Apr 2022 Results assessing the effectiveness of safinamide on sleep and daytime sleepiness in Parkinson's disease (PD) patients published in the Neurological Sciences
22 Sep 2021 Primary endpoint (Non-motor symptoms scale (NMSS) total score) has been met, according to Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
22 Sep 2021 Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com